Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

NASDAQ:VNDA - Nasdaq - US9216591084 - Common Stock - Currency: USD

4.48  +0.17 (+3.94%)

After market: 4.48 0 (0%)

Fundamental Rating

4

Taking everything into account, VNDA scores 4 out of 10 in our fundamental rating. VNDA was compared to 572 industry peers in the Biotechnology industry. VNDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VNDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

VNDA had negative earnings in the past year.
In the past year VNDA has reported a negative cash flow from operations.
VNDA had positive earnings in each of the past 5 years.
Each year in the past 5 years VNDA had a positive operating cash flow.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

1.2 Ratios

With an excellent Return On Assets value of -2.54%, VNDA belongs to the best of the industry, outperforming 90.44% of the companies in the same industry.
VNDA has a Return On Equity of -3.03%. This is amongst the best in the industry. VNDA outperforms 92.39% of its industry peers.
Industry RankSector Rank
ROA -2.54%
ROE -3.03%
ROIC N/A
ROA(3y)2.32%
ROA(5y)7.05%
ROE(3y)2.74%
ROE(5y)8.3%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20

1.3 Margins

VNDA's Profit Margin has declined in the last couple of years.
VNDA has a better Gross Margin (93.62%) than 95.04% of its industry peers.
VNDA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.23%
PM growth 5Y-36.93%
GM growth 3Y0.64%
GM growth 5Y0.65%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VNDA has more shares outstanding
The number of shares outstanding for VNDA has been increased compared to 5 years ago.
VNDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

VNDA has an Altman-Z score of 1.83. This is not the best score and indicates that VNDA is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.83, VNDA is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
VNDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.83
ROIC/WACCN/A
WACC10.71%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

VNDA has a Current Ratio of 4.85. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA has a Current ratio (4.85) which is in line with its industry peers.
A Quick Ratio of 4.84 indicates that VNDA has no problem at all paying its short term obligations.
The Quick ratio of VNDA (4.84) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.85
Quick Ratio 4.84
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -233.33%.
VNDA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -36.12% yearly.
VNDA shows a decrease in Revenue. In the last year, the revenue decreased by -9.91%.
VNDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.05% yearly.
EPS 1Y (TTM)-233.33%
EPS 3Y-51.19%
EPS 5Y-36.12%
EPS Q2Q%N/A
Revenue 1Y (TTM)-9.91%
Revenue growth 3Y-8.1%
Revenue growth 5Y-0.05%
Sales Q2Q%22.76%

3.2 Future

The Earnings Per Share is expected to grow by 174.15% on average over the next years. This is a very strong growth
Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 5.50% on average per year.
EPS Next Y-752.8%
EPS Next 2Y103.66%
EPS Next 3Y174.15%
EPS Next 5YN/A
Revenue Next Year8.16%
Revenue Next 2Y24.3%
Revenue Next 3Y21.37%
Revenue Next 5Y5.5%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 21.60, the valuation of VNDA can be described as rather expensive.
Based on the Price/Forward Earnings ratio, VNDA is valued cheaply inside the industry as 94.34% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.74, VNDA is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 21.6
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as VNDA's earnings are expected to grow with 174.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.66%
EPS Next 3Y174.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (2/4/2025, 8:14:40 PM)

After market: 4.48 0 (0%)

4.48

+0.17 (+3.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-05 2025-02-05/amc
Inst Owners76.88%
Inst Owner Change-0.73%
Ins Owners3.07%
Ins Owner Change-0.13%
Market Cap261.23M
Analysts80
Price Target10.64 (137.5%)
Short Float %5.82%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.31%
Min EPS beat(2)45.98%
Max EPS beat(2)62.65%
EPS beat(4)3
Avg EPS beat(4)-18.05%
Min EPS beat(4)-237.25%
Max EPS beat(4)62.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.78%
Min Revenue beat(2)-4.96%
Max Revenue beat(2)3.39%
Revenue beat(4)2
Avg Revenue beat(4)3.58%
Min Revenue beat(4)-4.96%
Max Revenue beat(4)19.95%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)29.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)34.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.6
P/S 1.37
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)0.21
Fwd EY4.63%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.27
BVpS9.28
TBVpS7.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.54%
ROE -3.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.62%
FCFM N/A
ROA(3y)2.32%
ROA(5y)7.05%
ROE(3y)2.74%
ROE(5y)8.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.23%
PM growth 5Y-36.93%
GM growth 3Y0.64%
GM growth 5Y0.65%
F-Score2
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.59%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.85
Quick Ratio 4.84
Altman-Z 1.83
F-Score2
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)19.78%
Cap/Depr(5y)31.18%
Cap/Sales(3y)0.23%
Cap/Sales(5y)0.37%
Profit Quality(3y)394.44%
Profit Quality(5y)287.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-233.33%
EPS 3Y-51.19%
EPS 5Y-36.12%
EPS Q2Q%N/A
EPS Next Y-752.8%
EPS Next 2Y103.66%
EPS Next 3Y174.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.91%
Revenue growth 3Y-8.1%
Revenue growth 5Y-0.05%
Sales Q2Q%22.76%
Revenue Next Year8.16%
Revenue Next 2Y24.3%
Revenue Next 3Y21.37%
Revenue Next 5Y5.5%
EBIT growth 1Y-15514.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.78%
EBIT Next 3Y38.33%
EBIT Next 5YN/A
FCF growth 1Y-137.44%
FCF growth 3Y-37.14%
FCF growth 5Y21.97%
OCF growth 1Y-135.85%
OCF growth 3Y-37.25%
OCF growth 5Y-15.66%